This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

EGT-201

Esteve, S.A.

Drug Names(s): AAV Sanfilippo IIIB, adeno-associated viral vector serotype 9 containing human N-acetylglucosaminidase alpha gene, MPS IIIB Gene Therapy (Esteve), EGT201, EGT 201

Description: Esteve is developing a viral gene therapy that contains the human N-acetylglucosaminidase alpha gene for the treatment of mucopolysaccharidosis III type B.

Deal Structure: The project Sanfilippo is developed under a Public-Private Partnership (PPP) between Esteve and the UAB (Universitat Autnoma de Barcelona) for the development of gene therapies for mucopolysaccharidosis.


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug